Key points
- Recce Pharmaceuticals reported significant clinical and operational milestones
- Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia initiated
- Positive preclinical data for RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia
- Strategic licensing term sheet signed with a leading Middle Eastern pharmaceutical company
- U.S. Government collaborations expanded
Full summary
Recce Pharmaceuticals Ltd reported significant clinical and operational milestones for the financial year ended 30 June 2026. Key highlights include the initiation of the Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia, with five clinical study sites activated. Positive preclinical data for RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia were also reported, showing a 4-log reduction in bacterial burden. The company signed a strategic licensing term sheet with a leading Middle Eastern pharmaceutical company, covering 12 countries across the MENA region. Additionally, U.S. Government collaborations expanded, with a second Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research, and positive preclinical efficacy data for R327G against MRSA and Pseudomonas aeruginosa in burn wound rat infection models.